Beximco Pharmaceuticals PLC. announcements
297 Dhaka Stock Exchange announcements for Beximco Pharmaceuticals PLC. (BXPHARMA) since 2007: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2022 (16).
- Credit Rating Information and Services Limited (CRISL) has rated the Company as \"AAA\" in the long term and \"ST-1\" in
Credit Rating Information and Services Limited (CRISL) has rated the Company as \"AAA\" in the long term and \"ST-1\" in the short term along with a stable outlook in consideration of its audited financials up to June 30, 2022; un-audited financial up to September 30, 2022 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
- Resumption after record date
Trading of the shares of the Company will resume on 22.11.2022 after record date.
- Suspension for Record date
Trading of the shares of the Company will remain suspended on record date i.e., 21.11.2022.
- Spot News
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with cum benefit from 17.11.2022 to 20.11.2022. Trading of the shares of the Company will remain suspended on record date i.e., 21.11.2022.
- (Q1 Un-audited): Consolidated EPS was Tk. 3.24 for July-September 2022 as against Tk. 3.28 for July-September 2021; Cons
(Q1 Un-audited): Consolidated EPS was Tk. 3.24 for July-September 2022 as against Tk. 3.28 for July-September 2021; Consolidated NOCFPS was Tk. 1.53 for July-September 2022 as against Tk. 4.46 for July-September 2021. NAV per share was Tk. 94.25 as on September 30, 2022 and Tk. 86.31 as on September 30, 2021. Reasons for significant deviation: Consolidated Earnings Per Share (EPS) for the period July-September 2022 has declined (cont.)
- Q1 Financials
(Continuation news of BXPHARMA): due to decreased EPS of the subsidiary Nuvista Pharma and loss incurred by the other newly acquired subsidiary Synovia Pharma. Net Operating Cash Flow per share declined as against comparable prior period due to increased working capital investment consequent to the record devaluation of Taka, increased price of materials and higher domestic inflation. (end)
The first part of this announcement is missing from the archive. - Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 10, 2022 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2022.
- Price Limit Open
There will be no price limit on the trading of the shares of the Company today (30.10.2022) following its corporate declaration. However, as per the BSEC Order No. BSEC/CMRRCD/2001-07/39 dated July 28, 2022, the floor price shall be applicable accordingly.
- Dividend Declaration
The Board of Directors has recommended 35% cash dividend for the year ended June 30, 2022. Date of AGM: 22.12.2022, Time: 10:30 AM, Venue: Digital Platform. Record Date: 21.11.2022. The Company has also reported EPS of Tk. 11.48, NAV per share of Tk. 91.01 and NOCFPS of Tk. 11.69 for the year ended June 30, 2022 as against Tk. 11.49, Tk. 83.01 and Tk. 13.50 respectively for the same period of the previous year.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 27, 2022 at 3:30 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2022.
- Q3 Financials
(Q3 Un-audited): Consolidated EPS was Tk. 2.47 for January-March 2022 as against Tk. 3.28 for January-March 2021; Consolidated EPS was Tk. 9.60 for July 2021-March 2022 as against Tk. 8.23 for July 2020-March 2021. Consolidated NOCFPS was Tk. 8.88 for July 2021-March 2022 as against Tk. 9.05 for July 2020-March 2021. Consolidated NAV per share was Tk. 89.13 as on March 31, 2022 and Tk. 79.73 as on March 31, 2021.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 27, 2022 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2022.
- (Q2 Un-audited): Consolidated EPS was Tk. 3.84 for October-December 2021 as against Tk. 2.54 for October-December 2020;
(Q2 Un-audited): Consolidated EPS was Tk. 3.84 for October-December 2021 as against Tk. 2.54 for October-December 2020; Consolidated EPS was Tk. 7.12 for July-December 2021 as against Tk. 4.95 for July-December 2020. Consolidated NOCFPS was Tk. 8.22 for July-December 2021 as against Tk. 4.91 for July-December 2020. Consolidated NAV per share was Tk. 86.65 as on December 31, 2021 and Tk. 76.45 as on December 31, 2020. (Cont.)
- Q2 Financials
(Continuation news of BXPHARMA): The company achieved over 17% growth in consolidated sales as compared to prior period. Moreover, other income also increased predominantly due to income from vaccine distribution fee which was not there in the comparative prior period. These have contributed towards increase in consolidated earning per share. Consolidated operating cash flow per share also increased due to higher revenue and improved net working capital. (end)
The first part of this announcement is missing from the archive. - Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 27, 2022 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2021.
- Dividend Disbursement
The Company has informed that it has disbursed the cash dividend for the year ended June 30, 2021 to the respective shareholders.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.